Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
STERIS plc is investing $600 million in a new formulated chemistries Center of Excellence in North Carolina, its largest single manufacturing site investment. This project aims to expand capacity, improve efficiency, and support demand for high-growth, high-margin products that generate over $700 million in revenue. While the initiative offers significant potential benefits like scale and automation, investors must also consider the increased capital spending, restructuring costs, and the multi-year execution risk involved before the project yields its target double-digit return on invested capital.
Steris stock holds above $230 as fiscal first-quarter earnings grow
Steris plc's stock is trading above $230 after the company reported increased fiscal first-quarter earnings and maintained its fiscal 2027 growth guidance. The company achieved adjusted earnings of $2.59 per share, a 10.7% increase year-over-year, and revenue of $1.49 billion, up 7.3%. Steris also saw its adjusted operating margin expand by 99 basis points, driven by higher volume, pricing actions, and a favorable mix of services and consumables, positioning it as a company balancing top-line expansion with cost control.
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STERIS (STE) is entering fiscal 2027 with steady healthcare demand and improving profitability, with its stock valuation below its five-year median. Despite broad operating momentum and a healthy backlog supporting recurring demand, the company faces risks from tariffs, softer sterilization volumes, and a significant investment in a new chemistry facility. The stock currently carries a Zacks Rank #3 (Hold), suggesting a measured stance rather than a clear buy signal.
Steris stock steadies after record chemistries investment and fiscal 2027 Q1 growth
Steris plc's stock is stabilizing in the low $230s after the company reported strong fiscal 2027 first-quarter growth and reaffirmed its full-year guidance. Investors are also digesting a significant $600 million investment plan for a new chemistries Center of Excellence in North Carolina. This investment underscores Steris's commitment to expanding its infection-prevention and procedural solutions, with a focus on high-margin, recurring revenue streams from consumables.
Steris PLC stock underperforms Wednesday when compared to competitors despite daily gains
Steris PLC's stock (STE) increased by 1.95% on Wednesday, reaching $236.91, marking its second consecutive day of gains. Despite this, the stock underperformed compared to its competitors, even though the broader market, including the S&P 500 Index and the Dow Jones Industrial Average, also saw gains.
Should STERIS’ (STE) Record Chemistries Investment and Reaffirmed Outlook Require Action From Investors?
STERIS (STE) reported strong Q1 fiscal 2027 results, including higher sales and increased earnings, and reaffirmed its full-year revenue growth guidance of 7% to 8%. The company also announced a record US$600 million investment in a chemistries Center of Excellence in North Carolina, highlighting management's confidence in its infection prevention chemistries business. This investment, combined with positive earnings and guidance, suggests a continued focus on high-margin consumables and services, though investors should monitor execution and potential regulatory risks.
Should STERIS’ (STE) Record Chemistries Investment and Reaffirmed Outlook Require Action From Investors?
STERIS plc (STE) recently reported strong Q1 fiscal 2027 results with increased sales and earnings, reaffirmed its full-year revenue growth guidance, and announced a record US$600 million investment in a chemistries Center of Excellence in North Carolina. This investment signals management's confidence in its infection prevention chemistries business and is a key factor to watch, as successful execution could reinforce growth, while delays or cost overruns could highlight regulatory and cost risks. The company's narrative projects significant revenue and earnings growth by 2029, suggesting a potential 13% upside to its current price.
STERIS plc (NYSE: STE) director lines up new stock sale after recent $310K trade
STERIS plc director Richard C. Breeden has filed a Rule 144 notice to sell up to 4,110 ordinary shares, valued at approximately $953,114.00, through Charles Schwab on the NYSE, with a target sale date of August 18, 2026. These shares were acquired on August 13, 2025, via an "Exercise & Hold" transaction. This proposed sale follows a previous transaction where Breeden sold 1,481 shares of STERIS plc on June 2, 2026, for $310,285.00.
Steris PLC stock outperforms competitors on strong trading day
Steris PLC's stock rose by 1.15% to $232.39 on Tuesday, despite a negative overall trading day for the stock market. This performance allowed Steris to outperform the S&P 500 Index and Dow Jones Industrial Average, which both saw declines. The rise also ended a five-day losing streak for the company's stock.
Ecolab Rallies 12.2% in 3 Months as High-Tech Growth Gains Momentum
Ecolab (ECL) shares have gained 12.2% in the past three months, driven by strong growth in its High-Tech, Digital, and Life Sciences segments, along with firm pricing and an optimistic 2026 earnings outlook. Despite this positive momentum, the company faces challenges from elevated debt, acquisition-related financing costs, and macroeconomic uncertainties. The stock currently holds a Zacks Rank #4 (Sell), tempering the outlook despite its recent rally.
Ecolab Rallies 12.2% in 3 Months as High-Tech Growth Gains Momentum
Ecolab Inc. (ECL) shares have gained 12.2% in three months, driven by strong performance in its High-Tech, Digital, and Life Sciences segments, along with firm pricing. The company raised its 2026 earnings outlook, targeting significant growth in its high-tech platforms. However, increased debt and acquisition-related financing costs are noted as potential offsets to continued upside.
Ecolab Rallies 12.2% in 3 Months as High-Tech Growth Gains Momentum
Ecolab (ECL) shares have gained 12.2% in the past three months, driven by strong growth in its High-Tech, Digital, and Life Sciences segments, firmer pricing, and a higher 2026 earnings outlook. Despite these positive trends, the company faces challenges from elevated debt, acquisition-related financing costs, and macroeconomic uncertainty. The report also highlights a cautious Zacks Rank #4 (Sell) due to higher leverage and near-term acquisition costs, even with a strong Momentum Score.
Steris stock holds steady as valuation and earnings support long-term growth
Steris plc (STE) stock is showing a solid market capitalization and its recent earnings support its current valuation, trading in the low-$230s with a market cap of $22.41 billion. The company, a leader in healthcare sterilization and infection prevention, has a trailing P/E of 28.85 and a consensus Buy rating from analysts with a price target of $265.99, suggesting potential upside. Steris's business model focuses on critical infection prevention solutions for healthcare, including advanced sterilization and decontamination systems.
Steris PLC stock underperforms Monday when compared to competitors
Steris PLC stock (STE) fell 1.51% to $229.75 on Monday, marking its fifth consecutive day of losses. This underperformance occurred on a generally poor trading day where the S&P 500 Index (SPX) dropped 0.52% and the Dow Jones Industrial Average (DJIA) fell 0.51%. The decline indicates that Steris PLC's stock did not fare as well as its competitors on this particular day.
KeyBanc Maintains Steris PLC(STE.US) With Buy Rating, Maintains Target Price $269
KeyBanc has reiterated its Buy rating on Steris PLC (STE.US) and maintained its price target of $269. The analyst's decision indicates continued confidence in the company's financial performance and future prospects.
Stoneridge Investment Partners LLC Invests $1.03 Million in STERIS plc $STE
Stoneridge Investment Partners LLC initiated a new position in STERIS plc, valued at approximately $1.03 million, during the second quarter. Other institutional investors also adjusted their holdings, with 94.69% of the stock owned by hedge funds and institutions. Despite recent insider selling totaling $2.51 million, analysts maintain a "Moderate Buy" rating with an average price target of $271.33, and STERIS has increased its quarterly dividend.
Steris PLC stock outperforms competitors despite losses on the day
Steris PLC stock (STE) fell 1.18% to $233.28 on Friday, marking its fourth consecutive day of losses. Despite this, the stock outperformed the broader market, as the S&P 500 Index (SPX) dropped 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%.
West Pharmaceutical Services (NYSE:WST) Rating Lowered to Hold at Zacks Research
Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from "strong buy" to "hold" despite the company reporting strong quarterly results, exceeding EPS and revenue estimates. The broader analyst consensus remains a "Moderate Buy" with an average price target of $368.08. West Pharmaceutical Services posted Q2 EPS of $2.37 on revenue of $872.3 million, a 13.8% increase year-over-year, and forecast full-year 2026 EPS between $8.85 and $9.05.
Titan Acquisition Corp Reports Q2 2026 10-Q Filing with $290.7M in Trust Account
Titan Acquisition Corp (NASDAQ: TACH) filed its Q2 2026 10-Q report, revealing a trust account balance of $290.7 million, an increase from the previous period. The company reported a net income of $3.9 million for the first six months of 2026 and confirmed its status as a shell company. Its securities are traded on The Nasdaq Stock Market LLC.
STERIS plc (STE) director logs option exercise, share sale and new awards
STERIS plc director Mohsen Sohi engaged in several equity transactions, exercising 4,058 options and selling the corresponding shares for approximately $957K. Sohi also received new grants of 1,099 nonqualified stock options and 1,229 Career Restricted Stock Units. These transactions reflect recent insider activity at STERIS, detailing both the sale of exercised shares and new equity awards.
Chemed Corp (CHE) Stock Forecasts
Argus has lowered its target price for Chemed Corp (CHE) to $564.00, citing the company's business activities of purchasing, operating, and divesting subsidiaries to maximize shareholder value. As of the report date, Chemed Corp's current price is $540.25. The report suggests upgrading to premium research for more detailed insights.
STERIS (NYSE:STE) Director Sells $956,795.24 in Stock
STERIS (NYSE:STE) Director Mohsen Sohi sold 4,058 shares of the company's stock for a total of $956,795.24, reducing his direct holdings by 14.31% to 24,305 shares. This transaction followed the company's strong earnings report, where STERIS beat analyst EPS estimates and saw revenue rise by 7.3%. STERIS also increased its quarterly dividend and received a "Moderate Buy" consensus rating from analysts.
STERIS plc (STE) director Holland receives 1,025 Career Restricted Stock Units
STERIS plc director Christopher S. Holland was granted 1,025 Career Restricted Stock Units (RSUs). These RSUs are fully vested immediately and represent the right to receive one ordinary share each, to be settled six months after his Board service concludes. Following this grant, Holland directly holds 5,989 Career Restricted Stock Units.
STERIS plc (STE) director Pierre Boulud receives 1,025 Career RSUs
STERIS plc director Pierre Boulud was granted 1,025 Career Restricted Stock Units (RSUs), which are fully vested immediately but will be settled in ordinary shares six months after he ceases Board service. This grant brings his total direct RSU holdings to 1,392 units. Each RSU represents the right to receive one STERIS ordinary share.
STERIS plc SEC Filing (Aug 12, 2026)
This article reports on an SEC Form 144 filing by STERIS plc (STE) on August 12, 2026, detailing a proposed sale of 4058 shares of ordinary stock by an individual through an employee stock option exercise. The filing, which has a neutral impact and sentiment, provides information about the transaction, the acquiring party, and previous sales.
Jefferies Adjusts Price Target on STERIS to $232 From $225, Maintains Hold Rating
Jefferies has adjusted its price target for STERIS plc (STE) to $232, up from $225, while retaining a "Hold" rating on the stock. This update comes amidst other analyst revisions, with UBS also recently adjusting its price target for STERIS. The article highlights recent company news, including STERIS's Q1 2027 earnings results and plans for a $600 million investment in a new manufacturing facility.
Assenagon Asset Management S.A. Has $16.10 Million Stake in STERIS plc $STE
Assenagon Asset Management S.A. significantly increased its stake in STERIS plc by 56.5% during the second quarter, now holding 76,440 shares valued at $16.10 million. Institutional investors collectively own 94.69% of STERIS, which recently exceeded earnings expectations with $2.59 EPS and $1.49 billion in revenue, prompting a dividend increase. Despite some analyst price target reductions, the company maintains a consensus "Moderate Buy" rating with an average target price of $271.33.
Insulet Corporation (PODD) Stock forecasts
This article provides a stock forecast for Insulet Corporation (PODD), highlighting Morningstar's analysis from August 5, 2026. The report focuses on Insulet's solid quarterly earnings but anticipates a deceleration in the second half of the year. Insulet, founded in 2000, is known for its Omnipod system, which simplifies continuous subcutaneous insulin infusion therapy for diabetes.
AptarGroup, Inc. (ATR) Stock Forecasts
Argus has lowered its target price for AptarGroup, Inc. (ATR) to $150.00 from its current price of $135.42. AptarGroup, headquartered in Crystal Lake, Illinois, is a leading global supplier of dispensing systems for consumer goods and pharmaceutical markets. The report was published on August 05, 2026, by Argus.
Did STERIS’ (STE) Record Chemistries Bet and Dividend Hike Just Recast Its Earnings Narrative?
STERIS plc (STE) recently reported strong Q1 fiscal 2027 results, including increased sales and earnings, a reaffirmed full-year outlook, and its 21st consecutive annual dividend increase. The company also announced a significant US$600 million investment in a new chemistries Center of Excellence in North Carolina. This strategic move reinforces STERIS's focus on recurring, compliance-driven revenue streams in infection prevention, though investors should still consider risks like hospital budget pressures and rising input costs.
UBS Maintains Steris PLC(STE.US) With Buy Rating, Cuts Target Price to $270
UBS has reiterated its Buy rating for Steris PLC (STE.US) but has reduced the target price for the company's stock to $270. This adjustment reflects a continued positive outlook on Steris PLC despite a revised valuation.
STERIS plc (Ireland) (STE) Stock Forecasts
STERIS plc (STE) is a medical technology company specializing in sterilization services and infection prevention, holding a leading position in contract sterilization. A recent Morningstar report highlights the company's healthy fundamentals, which are enabling accelerated share repurchases and increased investment. The report provides a current stock price of $237.47 and notes the company's strong economic moat and stewardship.
CONMED Corporation (CNMD) Stock Forecasts
Argus has raised its target price for CONMED Corporation (CNMD) to $53.00. The medical equipment company, based in Utica, New York, specializes in sports medicine procedures and general surgeries. The current stock price for CNMD is $49.12.
Needham Maintains Steris PLC(STE.US) With Hold Rating
Needham has reiterated its Hold rating on Steris PLC (STE.US). This indicates that the analyst firm is advising investors to maintain their current position in the stock without buying or selling.
Steris PLC stock outperforms competitors on strong trading day
Shares of Steris PLC (STE) rose 2.45% on Friday to $237.47, outperforming the broader market which also saw gains with the S&P 500 Index up 0.62% and the Dow Jones Industrial Average rising 0.28%. This strong performance ended a two-day losing streak for the company's stock.
STERIS plc 2026: Revenue $1.49B, EPS $2.04— 10-Q Summary
STERIS plc (STE) reported its 2026 quarterly results with revenue of $1.49 billion and diluted EPS of $2.04, marking significant year-over-year growth in both metrics. The revenue increase of 7.3% was driven by higher volume and pricing, especially in Healthcare and Life Sciences, with strong recurring revenue from consumables and services. The company also completed three acquisitions in FY2027 and announced plans for a North Carolina Center of Excellence.
UBS Adjusts Price Target on STERIS to $270 From $275, Maintains Buy Rating
UBS has adjusted its price target for STERIS (NYSE: STE) to $270, down from $275, while reaffirming a Buy rating on the stock. This revision comes as analysts reassess the company's valuation. Despite the slight reduction in the price target, UBS continues to recommend STERIS as a purchase.
Narrow-Moat Steris' Recurring Revenue and Margin Improvement Create Opportunistic Outlook
Steris, a narrow-moat company, is a leading provider of sterilization products and services in healthcare. Recent acquisitions have expanded its portfolio, positioning it as a "one-stop shop" for outpatient settings. The company's focus on recurring revenue and margin improvements suggests an opportunistic outlook, further supported by healthy fundamentals allowing for accelerated repurchases and investment.
STERIS plc (STE) Stock Price, News, Quote & History
This article provides a comprehensive overview of STERIS plc (STE) stock, including its current price, dividend information, key financial metrics, and company profile. It details the company's segments in Healthcare, Applied Sterilization Technologies, and Life Sciences, and offers performance benchmarks against the S&P 500, earnings trends, analyst insights, and valuation measures. The article also includes a comparison tool for similar medical device companies.
STERIS plc (STE) Stock News Today
This page provides current stock information for STERIS plc (STE), including its market price, market capitalization, P/E ratio, and recent performance. It indicates that more news and earnings updates for the company will be available soon. The platform, TradingKey, offers general investment information and warns about investment risks.
Piper Sandler Maintains Steris PLC(STE.US) With Buy Rating, Cuts Target Price to $270
Piper Sandler has reiterated its Buy rating on Steris PLC (STE.US) but has reduced the target price to $270. This adjustment reflects an updated valuation while maintaining a positive outlook on the company's stock.
UBS Adjusts Price Target on STERIS to $270 From $275, Maintains Buy Rating
UBS has adjusted its price target for STERIS plc (STE) shares to $270, down from the previous $275, while reaffirming a Buy rating on the stock. This update reflects a slight modification in the firm's valuation outlook for the medical equipment and supplies provider. The article also mentions recent STERIS news, including a dividend increase and an investment in a new manufacturing facility.
STERIS plc (Ireland) Stock 12‑Month Price Target Cut to $260.67, Implies 12% Upside
The average 12-month price target for STERIS plc (Ireland) stock has been lowered from $265.57 to $260.67 by 6 analysts, suggesting a potential 12% upside from its Aug. 5 closing price. Despite the reduction, the consensus rating from 11 analysts remains a "Buy," with 7 recommending Buy and 4 recommending Hold. Investors can find more detailed price target data and analyst recommendations on TradingView's Forecasts tab and News Flow.
Earnings call transcript: STERIS beats Q1 2026 EPS, shares fall on spending plans
STERIS plc reported Q1 2027 earnings that beat analyst estimates but saw its shares fall due to investor concerns over increased capital spending plans, including a new $600 million manufacturing facility in North Carolina, and softer near-term segment trends. Despite the earnings beat and revenue matching expectations, the company's unchanged full-year guidance and higher capital expenditure forecast for fiscal 2027 led to a cautious market reaction. Management defended the investment as essential for long-term growth and capacity expansion, especially for its high-growth, high-margin formulated chemistries business.
Steris Posts Solid Q1 Results Amid Restructuring Plans
STERIS (STE) reported strong fiscal 2027 first-quarter results with 7% revenue growth and increased EPS, driven by its Healthcare segment and solid gains in Life Sciences and Applied Sterilization Technologies. The company announced a restructuring plan involving facility consolidations, incurring estimated charges of $55-70 million through fiscal 2030, while reiterating its revenue and earnings outlook for fiscal 2027. Analysts maintain a "Buy" rating for STE stock with a $275.00 price target, supported by strong financial performance and a constructive earnings outlook, despite some technical and valuation concerns.
Medical equipment company to close St. Louis-area plant as it moves work to new $600M facility in NC
A global medical equipment company is planning to invest $600 million in a new manufacturing and distribution hub in North Carolina. This development will result in the closure of its existing St. Louis-area plant, with operations being consolidated into the new facility. The move aims to centralize production and distribution for the company.
STERIS Plans $600M Chemical Manufacturing Hub, Q1 EPS Jumps 11% to $2.59
STERIS announced its largest single-site investment, a $600 million Formulated Chemistry Center of Excellence in North Carolina, alongside strong first-quarter fiscal 2027 results. The company reported an 11% increase in adjusted EPS to $2.59 and maintained its full-year revenue and EPS guidance, despite increased capital spending for the new facility. Growth was driven by healthcare services and consumables, and life sciences capital equipment, with a projected recovery in AST services in the second half.
Earnings call transcript: STERIS beats Q1 2026 EPS, shares fall on spending plans
STERIS plc reported strong fiscal Q1 2027 earnings, surpassing Wall Street expectations with $2.59 EPS, but its shares fell due to investor concerns over increased capital spending, restructuring costs, and softer segment trends. The company announced a $600 million investment in a new manufacturing center in North Carolina, its largest single-site investment, aimed at expanding capacity and optimizing its chemistry manufacturing and distribution network. Despite the stock drop, STERIS maintained its full-year guidance for fiscal 2027, projecting continued revenue and EPS growth, with the new facility expected to generate a significant return on invested capital within three to five years.
Cetera Investment Advisers Sells 17,585 Shares of STERIS plc $STE
Cetera Investment Advisers significantly reduced its stake in STERIS plc by selling 17,585 shares, decreasing its holdings by 54.3%. Despite this, institutional investors and hedge funds collectively own a large portion of the company's stock, which recently reported strong quarterly earnings, beating estimates, and increased its quarterly dividend. Analysts maintain a "Moderate Buy" rating for STERIS with a positive price target, even as the company plans major investments and some insider selling has occurred.
Should STERIS' (STE) Record Chemistries Investment and Dividend Hike Require Action From Investors?
STERIS plc (STE) plans to invest US$600 million in a new 600,000 square-foot chemistries Center of Excellence in North Carolina, creating 335 jobs and consolidating production. This investment, alongside a dividend hike for the 21st year and solid Q1 fiscal 2027 revenue growth, reinforces the company's focus on infection prevention. The article suggests investors should consider this major investment in the context of STERIS's recurring revenue model, reaffirmed guidance, and potential challenges like rising tariffs.
